EUCTR2018-002473-21-CZ进行中（未招募）1 期
An Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects with Acute HIT (HITSOVA study) - HITSOVA
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 508
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •At the time of enrollment subjects are eligible to be included in the study only if all of the following criteria apply:
- •1.Signed written informed consent by the subject who is able to assess the nature, significance and scope of the clinical trial. If the subject is in emergency situation and temporarily incapable of consent, the consent of a legal representative or authorised representative will be waived if permitted under applicable local regulations/ethics committee recommendations. Consent must be obtained for further participation in the clinical trial as soon as this is possible and reasonable for the subject to do so to confirm understanding/willingness to participate in the clinical study and ability to comply with study procedures and the study visit schedule. Males or females aged =2 weeks
- •2.Subjects with suspected HIT by 4Ts of >3 and with reduction of platelet count of = 30% at either:
- •a) Between Day 4 and 14 of the start of heparin exposure or
- •b) At Day 1 of heparin exposure with pre-treatment with heparin within the last 30 days,
- •with or without thrombosis.
- •3.Have adequate renal function: estimated glomerular filtration rate (eGRF) = 15 mL/min/1.73 m²
- •4.Male participants:
- •A male participant must agree to use contraception during the treatment period and for at least 5 days after the last dose of study intervention and refrain from donating sperm during this period.
- •5.Female participants:
- •A female participant is eligible to participate if 1 of the following conditions applies:
- •a.Not a woman of childbearing potential
- •b.A woman of childbearing potential who agrees to follow the contraceptive guidance during the treatment period and during the entire VKA use and for one month after cessation of its use. Subjects should continue with adequate contraception after the study end if they continue with VKA use. (Subjects taking oral contraceptives or hormone replacement therapy must have a stable dose and regimen for = 3 months prior to entry into the study.)
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 12
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 486
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •At the time of enrollment subjects are excluded from the study if any of the following criteria apply:
- •1.Premature infants (corrected age <37 weeks gestational age)
- •2.Expectation of cardiac surgery within the next 44 days
- •3.Life expectancy clearly less than the 44 days
- •4.Fibrinolytic therapy <24 hours before enrollment
- •5.Lumbar puncture or spinal/epidural catheter placement within the past 48 hours
- •6.Severe hepatic impairment (Child-Pugh Class C) Note: in patients with suspected/confirmed severe liver disease, Child-Pugh C stage of liver disease must be excluded before start of treatment. For calculating Child-Pugh score, laboratory parameters in the patient file on INR, prothrombin time, serum albumin and total bilirubin taken can be taken, if they have been obtained within the last 48 hours before randomization. In all other patients these parameters have to be measured before start of treatment to identify potential exclusion criteria.
- •7.Active bleeding
- •8.Subjects with the following conditions to be excluded if alternative antithrombotic treatments are available:
- •(i)Severe hemorrhagic diathesis,
- •(ii)Traumatic damage to the central nervous system
- •(iii)Brain, spinal or ophthalmologic surgery
- •(iv)Active stomach/duodenal ulcers or active peptic ulcer unless this ulcer is the cause of the surgical procedure
- •9.An unexplained activated partial thromboplastin time (aPTT) > 2 x the normal range
- •10.A hemorrhagic cerebrovascular accident within the previous 3 months
- •11.Severe, uncontrolled hypertension defined as blood pressure >180/110 mmHg
- •12.Diabetic retinopathy
- •13.Acute bacterial endocarditis
- •14.Expectation of a long-term (> 3 weeks) hemodialysis requirement before the end of the acute treatment
- •15.Hypersensitivity to the active substances or to any of the excipients
- •16.Hypersensitivity to sulphite
- •17.Any investigational drug(s) use within 4 weeks preceding screening or anticipated use during the course of the study
- •18.Pregnant or breastfeeding woman
- •19.Use of intra-aortic balloon pump, or ventricular assist device
研究者
相似试验
进行中（未招募）
1 期
The study evaluates the safety and efficacy of danaparoid vs argatroban in treatment of subjects with acute heparin-induced-thrombocytopenia (HITSOVA)EUCTR2018-002473-21-DEAspen Global Incorporated508
进行中（未招募）
1 期
The study evaluate the safety and efficacy of danaparoid vs argatroban in treatment of subjects with acute heparin-induced-thrombocytopenia (HITSOVA)Acute Heparin-induced Thrombocytopenia (HIT)MedDRA version: 20.0 Level: PT Classification code 10062506 Term: Heparin-induced thrombocytopenia System Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2018-002473-21-ESAspen Global Incorporated508
进行中（未招募）
1 期
The study evaluate the safety and efficacy of danaparoid vs argatroban in treatment of subjects with acute heparin-induced-thrombocytopenia (HITSOVA)Acute Heparin-induced Thrombocytopenia (HIT)MedDRA version: 20.0Level: PTClassification code 10062506Term: Heparin-induced thrombocytopeniaSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2018-002473-21-ITAspen Global Incorporated7
进行中（未招募）
1 期
The study evaluates the safety and efficacy of danaparoid vs argatroban in treatment of subjects with acute heparin-induced-thrombocytopenia (HITSOVA)Acute Heparin-induced Thrombocytopenia (HIT)MedDRA version: 20.0Level: PTClassification code 10062506Term: Heparin-induced thrombocytopeniaSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2018-002473-21-HRAspen Global Incorporated508
进行中（未招募）
1 期
The study evaluate the safety and efficacy of danaparoid vs argatroban in treatment of subjects with acute heparin-induced-thrombocytopenia (HITSOVA)Acute Heparin-induced Thrombocytopenia (HIT)MedDRA version: 20.0 Level: PT Classification code 10062506 Term: Heparin-induced thrombocytopenia System Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2018-002473-21-PLAspen Global Incorporated508